ThioBridge™ next-generation conjugation technology
ThioBridge™ conjugation technology has been proven to enhance ADC development by overcoming issues with existing technologies in order to improve stability, potency, and efficacy.
Receive your quote directly from the manufacturer.
Abzena's unique ThioBridge™ platform is truly next-generation conjugation technology. It overcomes some of the shortcomings of first-generation conjugation technologies, by using site-specific conjugation to antibody interchain disulfide. It offers a more uniform DAR profile and stable attachment compared to maleimide conjugation and allows for PK profiles to be optimized with architectural design flexibility when it comes to the payload and spacer.
ThioBridge Advantages:
Site-specific attachment at the interchain disulfides
- Ag+ binding
- Homogeneous DAR
- Stable linker
Modulate Binding to Fc receptors
- Lower FcyR binding
- Intact FcRn binding
- Versatile
All payload classes, and architectural design for DAR optimization.
